# LLM Council Transcript — Discovery Legs vs ALPHA_V1 Portfolio

**Date**: April 3, 2026
**Session ID**: 20260403-144421

---

## Original Question

Should any of the 3 council-recommended discovery legs (NQ Asia-B, GC Asia-1, CL LDN-1) be added to or replace legs in the current ALPHA_V1 portfolio? The portfolio has 4 live legs (NQ NY LSI, NQ Asia ORB, ES Asia ORB, ES NY ORB) — all long-only equity index on Apex Trader Funding with known concentration risk. GC is banned on Apex.

---

## Framed Question

Evaluate whether three freshly backtested discovery legs should modify a live prop firm portfolio. Key tensions: (1) NQ Asia-B trades the same session as a live leg with worse lifetime metrics, (2) GC provides genuine diversification but is platform-banned, (3) CL had a near-flat 2025. The portfolio's known existential weakness is all-long-equity-index concentration with zero commodity exposure.

---

## Advisor Responses

### The Contrarian

No to all three. NQ Asia-B is concentration, not diversification — same instrument, same session, same direction. If NQ Asia has a regime shift, both legs blow up together. The param difference is noise compared to the shared underlying risk factor.

GC is not a discussion. It is banned on Apex. The question should not appear on this council.

CL LDN-1 is the worst candidate in the set. +2.1R in 2025 on a strategy being evaluated for 2025-era prop firm farming is disqualifying. DSR of 0.186 is near-random. A -19.9R max DD will hit the -4R breach threshold repeatedly.

The real fatal flaw nobody is addressing: all four live legs are long-only equity index. The discovery legs offer GC (banned) and CL (broken). If equity indices enter a sustained bear regime, the entire portfolio breaches simultaneously. Fix that first. Do not expand until a non-correlated, non-equity leg is found that actually works in 2025.

### The First Principles Thinker

What are we actually solving? Not "which leg has the best backtest." We're solving: how do we maximize risk-adjusted payout frequency given zero live track record on the three discovery legs.

On NQ Asia-B vs. live NQ Asia ORB: Do not replace. The backtest is worse on every meaningful metric (Calmar 10.8 vs ~20+, Full R 138 vs 212, higher DD). Running both adds concentration with extra complexity.

On GC: banned on Apex. Non-starter unless running a different firm for this leg specifically.

On CL: +2.1R in 2025 with -19.9R max DD is the answer. DSR 0.186. No.

On removing current legs: Nothing justifies removing anything from ALPHA_V1.

On portfolio size: Stay at 4. The real diversification gap — commodity, short-side exposure — cannot be filled by any of these three legs. The discovery pipeline surfaced nothing that improves the current portfolio. That's the actual next problem to assign.

### The Expansionist

Run both NQ Asia legs. Add GC on a different prop firm. Delay CL. Target 6 legs total.

NQ Asia-B: Add, don't replace. The live leg has $212R full history — you don't pull that. But Asia-B's regime gate is a fundamentally different signal source. Two NQ Asia accounts isn't concentration risk, it's uncorrelated entry logic on the same instrument.

GC Asia-1: Yes, immediately, different prop firm. This is the single most urgent addition. Zero commodity exposure means every drawdown correlates. GC's DSR 0.652 is solid. TopStep and FTMO aren't Apex — confirm GC is tradeable, open accounts, fund now. The diversification value is worth more than standalone R numbers.

CL LDN-1: Not yet. 2025 at +2.1R plus 2-week pipeline = bad ROI. Revisit later.

Remove nothing. All four legs performing. Target 6 legs: NQ NY LSI + NQ Asia ORB + NQ Asia-B + ES Asia + ES NY + GC Asia-1. ~$5M+ lifecycle potential.

### The Outsider

New-Y (GC) is the only genuinely interesting proposal. Different sector, highest statistical confidence, real diversification. Platform switch is one-time friction, not recurring. If switch cost is under ~2 weeks, worth serious consideration.

New-X (NQ Asia-B): Lower efficiency (10.80 vs higher), lower lifetime (138 vs 212), identical segment and time window. Correlated duplicate with worse historical metrics. Do not swap, do not add.

New-Z (CL): 2025 near-flat, worst dip in entire set, statistical confidence of 0.186 near-random. Three independent failure signals. Hard no.

Remove nothing. Stay at 4, pursue GC only.

### The Executor

Monday morning plan:

NQ Asia-B: Run both, not replace. Live NQ Asia ORB is the single best leg (212R, 67d fastest payout). No justification to swap. Check trade log overlap first — if under 30%, add as fifth leg. Exec config is a weekend project.

GC: Not now. Apex bans it. New firm means applications, new management overhead, new rule sets, 3-4 weeks setup. Current 4 legs are printing. GC goes on watchlist.

CL: No. 2025 flat, worst DD, weak DSR. Don't build a pipeline for this.

Remove nothing. Keep all 4. Move to 5 legs max near-term.

Action: This weekend, pull NQ Asia trade logs and NQ Asia-B logs. Count overlap days. If under 30%, build exec config and shadow-run next week.

---

## Peer Reviews

### Anonymization Mapping
- Response A = The Executor
- Response B = The Expansionist
- Response C = The Outsider
- Response D = The First Principles Thinker
- Response E = The Contrarian

### Reviewer 1 (general)
**Strongest: D (First Principles)** — most rigorous, honest conclusion that discovery surfaced nothing useful. **Blind spot: B (Expansionist)** — treats ban as logistical inconvenience. **All missed:** pairwise return correlation analysis.

### Reviewer 2 (risk manager)
**Strongest: E (Contrarian)** — refuses to let activity masquerade as progress. **Blind spot: B (Expansionist)** — optimism without constraints. **All missed:** drawdown sequencing risk, joint loss distribution.

### Reviewer 3 (portfolio allocator)
**Strongest: E (Contrarian)** — prioritizes systemic risk before expansion. **Blind spot: B (Expansionist)** — urgency without evidence. **All missed:** prop firm daily loss limits under simultaneous adverse moves.

### Reviewer 4 (operations)
**Strongest: A (Executor)** — concrete sequenced action, correct first step. **Blind spot: B (Expansionist)** — multi-firm onboarding is not a weekend errand. **All missed:** correlation stress testing under regime change.

### Reviewer 5 (data scientist)
**Strongest: C (Outsider)** — instrument-specific reasoning grounded in metrics. **Blind spot: B (Expansionist)** — conflates signal independence with return independence. **All missed:** regime conditioning and portfolio-level MAE.

### Vote Tally
- Strongest: Contrarian (2), First Principles (1), Outsider (1), Executor (1)
- Biggest blind spot: Expansionist (5/5 unanimous)

---

## Chairman's Synthesis

### Where the Council Agrees

All five advisors reject CL LDN-1. +2.1R in 2025, DSR 0.186, -19.9R drawdown. Unanimous.

All five recognize the existential concentration risk: four long-only equity index legs on one prop firm. No one disputes this.

On NQ Asia-B: the majority correctly reads the metrics — 138R lifetime vs 212R for the live leg, no replacement case, and running both adds correlated risk without uncorrelated return.

### Where the Council Clashes

The central fight is over GC. The Expansionist calls it the most urgent addition. The Contrarian and First Principles call it a non-starter because of the Apex ban. The Outsider supports it with platform switch. The Executor says not now.

This is not a disagreement about GC's quality. DSR 0.652, genuine diversification, highest statistical confidence — no one disputes the signal. The disagreement is about operational sequencing and whether the platform switch is a blocker or a one-time cost.

The Expansionist loses this argument not because the reasoning about GC is wrong, but because it consistently underweights friction. The 5-reviewer consensus naming the Expansionist as the unanimous blind spot is the loudest signal in this council.

### Blind Spots the Council Caught

1. **Pairwise return correlation never computed.** Running NQ Asia-B alongside the live leg requires knowing actual return correlation, not assumed independence from different entry logic.

2. **Joint loss distribution under simultaneous adverse moves.** A single macro shock hits all four equity legs at once. No one modeled the combined daily loss against Apex's per-account limits.

3. **Regime conditioning.** Whether GC or NQ Asia-B signals are regime-dependent was never examined.

### The Recommendation

**Do not add NQ Asia-B.** The live leg is superior on every metric. Running both adds correlated exposure disguised as diversification.

**Do not add CL.** Unanimous.

**Add GC — but not on Apex, and not this week.** GC is the correct answer to the concentration problem. The only discovery leg with genuine diversification value and statistical confidence. Open a TopStep or FTMO account. 3-4 week timeline is correct.

**Keep all four current legs.** No removal case exists.

**Target 5 legs: current 4 + GC on a second firm.**

### The One Thing to Do First

Open a second prop firm account (TopStep or FTMO) this week. The concentration risk is known, the solution is known, and GC is on the bench because of a platform constraint within your control. The account application takes an afternoon. Everything else — overlap checks, further discovery — is second-order.

---

*Council session completed April 3, 2026. 5 advisors, 5 peer reviews, chairman synthesis.*
